Description: Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of chlamydia and gonorrhea in women. The company is also developing multi-purpose vaginal pH regulator gel product candidate for the reduction of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Home Page: www.evofem.com
EVFM Technical Analysis
12400 High Bluff Drive
San Diego,
CA
92130
United States
Phone:
858 550 1900
Officers
| Name | Title |
|---|---|
| Ms. Saundra Pelletier | Interim Chair, Pres & CEO |
| Mr. Justin J. File | Chief Financial Officer |
| Ms. Amy Raskopf | Sr. VP of Investor Relations |
| Kathy Gallo-Doyle | VP of Sales |
| Ms. Karina M. Fedasz | Head of Bus. Devel. |
| Ms. Katherine Atkinson | Chief Commercial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 8.372 |
| Price-to-Sales TTM: | 0.42 |
| IPO Date: | 2018-01-17 |
| Fiscal Year End: | December |
| Full Time Employees: | 119 |